Initial studies suggest that such therapies can improve insulin secretion, assist pancreatic beta cell preservation and enhance insulin-mediated glucose metabolism while reducing glucagon secretion and risk of fatty liver disease. The gene discussed is INS; the disease is fatty liver disease.